ZNF830
Gene Information
- Official Symbol: ZNF830
- Official Name: zinc finger protein 830
- Aliases and Previous Symbols: N/A
- Entrez ID: 91603
- UniProt: Q96NB3
- Interactions: BioGRID
- PubMed articles: Open PubMed
- OMIM: N/A
Function Summary
- Entrez Summary: N/A
- UniProt Summary: Acts as an important regulator of the cell cycle that participates in the maintenance of genome integrity. During cell cycle progression in embryonic fibroblast, prevents replication fork collapse, double-strand break formation and cell cycle checkpoint activation. Controls mitotic cell cycle progression and cell survival in rapidly proliferating intestinal epithelium and embryonic stem cells. During the embryo preimplantation, controls different aspects of M phase. During early oocyte growth, plays a role in oocyte survival by preventing chromosomal breaks formation, activation of TP63 and reduction of transcription. {ECO:0000250|UniProtKB:Q8R1N0}.
Pfam Domains GO Terms
Pfam Domains
No Pfam Domain information is available for this gene.
GO Terms
| multi-layer follicle stage |
| preantral ovarian follicle growth |
| intestinal epithelial structure maintenance |
| mammalian oogenesis stage |
| replication fork protection |
| mitotic DNA replication checkpoint |
| DNA replication checkpoint |
| blastocyst growth |
| maintenance of gastrointestinal epithelium |
| negative regulation of DNA-dependent DNA replication |
| epithelial structure maintenance |
| mitotic G2/M transition checkpoint |
| DNA-dependent DNA replication maintenance of fidelity |
| negative regulation of DNA replication |
| ovulation cycle process |
| nuclear DNA replication |
| cell cycle DNA replication |
| ovarian follicle development |
| regulation of DNA-dependent DNA replication |
| ovulation cycle |
| digestive system process |
| transcription-coupled nucleotide-excision repair |
| oogenesis |
| spliceosomal complex |
| female gonad development |
| negative regulation of G2/M transition of mitotic cell cycle |
| development of primary female sexual characteristics |
| mitotic DNA damage checkpoint |
| blastocyst development |
| negative regulation of cell cycle G2/M phase transition |
| mitotic DNA integrity checkpoint |
| female sex differentiation |
| regulation of DNA replication |
| nucleotide-excision repair |
| digestion |
| DNA-dependent DNA replication |
| chromosome |
| female gamete generation |
| DNA damage checkpoint |
| DNA integrity checkpoint |
| mitotic cell cycle checkpoint |
| tissue homeostasis |
| nucleic acid binding |
| cell cycle checkpoint |
| regulation of G2/M transition of mitotic cell cycle |
| gonad development |
| regulation of cell cycle G2/M phase transition |
| negative regulation of mitotic cell cycle phase transition |
| DNA replication |
| development of primary sexual characteristics |
| negative regulation of cell cycle phase transition |
| germ cell development |
| sex differentiation |
| rhythmic process |
| negative regulation of mitotic cell cycle |
| multicellular organismal homeostasis |
| negative regulation of cell cycle process |
| anatomical structure homeostasis |
| cellular process involved in reproduction in multicellular organism |
| in utero embryonic development |
| developmental growth |
| growth |
| RNA splicing |
| nuclear speck |
| regulation of mitotic cell cycle phase transition |
| reproductive structure development |
| reproductive system development |
| regulation of cell cycle phase transition |
| mRNA processing |
| cell division |
| DNA repair |
| negative regulation of cell cycle |
| mitotic cell cycle process |
| regulation of mitotic cell cycle |
| chordate embryonic development |
| embryo development ending in birth or egg hatching |
| developmental process involved in reproduction |
| mitotic cell cycle |
| gamete generation |
| mRNA metabolic process |
| DNA metabolic process |
| regulation of cell cycle process |
| cellular response to DNA damage stimulus |
| multicellular organismal reproductive process |
| sexual reproduction |
| zinc ion binding |
| multicellular organism reproduction |
| RNA processing |
| negative regulation of apoptotic process |
| negative regulation of programmed cell death |
| embryo development |
| multi-organism reproductive process |
| negative regulation of cell death |
| cell cycle process |
| chromosome organization |
| regulation of cell cycle |
| cell cycle |
| negative regulation of cellular macromolecule biosynthetic process |
| reproductive process |
| reproduction |
| negative regulation of macromolecule biosynthetic process |
| negative regulation of cellular biosynthetic process |
| regulation of apoptotic process |
| negative regulation of biosynthetic process |
| regulation of programmed cell death |
| homeostatic process |
| cell development |
| RNA metabolic process |
| regulation of cell death |
| cellular response to stress |
| cellular macromolecule biosynthetic process |
| macromolecule biosynthetic process |
| system process |
| gene expression |
CRISPR Data
Compound Hit Most Correlated Genes in Chemogenomics Tissues where Essential in the Avana Dataset (DepMap 20Q1)
Compound Hit
Most Correlated Genes in Chemogenomics
| Gene | Correlation |
|---|---|
| PSMA6 | 0.563 |
| PSMB4 | 0.552 |
| CHD4 | 0.539 |
| TCEB3C | 0.512 |
| CHAF1A | 0.509 |
| LRR1 | 0.508 |
| DNTTIP2 | 0.503 |
| CDC45 | 0.494 |
| COL2A1 | 0.492 |
| CBWD3 | 0.491 |
| NUPL1 | 0.489 |
| TBC1D3F | 0.488 |
| DHX38 | 0.488 |
| TSG101 | 0.488 |
| ARCN1 | 0.488 |
| TBC1D3H | 0.486 |
| RPS12 | 0.485 |
| TCEB3CL | 0.483 |
| RFC1 | 0.483 |
| PAN3 | 0.483 |
| POLE | 0.482 |
| PSMC2 | 0.482 |
| CTAGE4 | 0.481 |
| PSMB2 | 0.479 |
| CDC73 | 0.479 |
| COPE | 0.479 |
| MT1E | 0.478 |
| C1QTNF9B | 0.477 |
| CBWD6 | 0.477 |
| VPS28 | 0.477 |
| TCEB3CL2 | 0.476 |
| CCNA2 | 0.475 |
| CGB2 | 0.474 |
| ZFAND5 | 0.474 |
| CBWD5 | 0.473 |
| RANBP2 | 0.471 |
| PSMD11 | 0.471 |
| CACTIN | 0.47 |
| PSMC5 | 0.469 |
| NUP153 | 0.467 |
| TWISTNB | 0.466 |
| NSF | 0.466 |
| DDT | 0.465 |
| COPG1 | 0.465 |
| MKI67IP | 0.463 |
| TICRR | 0.463 |
| OSBP | 0.463 |
| NOL10 | 0.462 |
| DTL | 0.462 |
| TBC1D3G | 0.462 |
| ZNF655 | 0.462 |
| PDCD11 | 0.461 |
| SMG1 | 0.459 |
| DDTL | 0.459 |
| NUP160 | 0.459 |
| PSMD14 | 0.456 |
| IK | 0.455 |
| C2orf27B | 0.455 |
| ATP6V0C | 0.453 |
| ACSF2 | 0.451 |
| UPF1 | 0.451 |
| NPIPB5 | 0.45 |
| MED14 | 0.45 |
| RPL35 | 0.45 |
| ATP6V1B2 | 0.45 |
| NOL8 | 0.449 |
| CCDC94 | 0.448 |
| CDCA3 | 0.448 |
| RPS2 | 0.446 |
| PWP2 | 0.445 |
| AAMP | 0.444 |
| PPFIA4 | 0.444 |
| PSMB3 | 0.444 |
| STIL | 0.443 |
| SLC4A1 | 0.443 |
| CDT1 | 0.443 |
| MFSD12 | 0.443 |
| CDCA5 | 0.442 |
| CEP192 | 0.441 |
| PAF1 | 0.441 |
| PSMC1 | 0.44 |
| RPS28 | 0.439 |
| CMYA5 | 0.439 |
| ASF1B | 0.439 |
| SH3BP1 | 0.437 |
| RPS3 | 0.436 |
| PSMD3 | 0.436 |
| SLC6A17 | 0.436 |
| UTP3 | 0.436 |
| KCTD17 | 0.436 |
| POLA1 | 0.434 |
| TFIP11 | 0.434 |
| PSMA3 | 0.434 |
| GOLGA6L3 | 0.433 |
| TIMELESS | 0.432 |
| TBC1D3 | 0.431 |
| SAP30BP | 0.431 |
| RPL34 | 0.431 |
| SEC13 | 0.43 |
| PSMC6 | 0.43 |
| SUPT6H | 0.428 |
| XAB2 | 0.428 |
| GOLGA6L4 | 0.428 |
| TOP1MT | 0.427 |
| AKIRIN2 | 0.427 |
| PSMA7 | 0.427 |
| TP53TG3B | 0.427 |
| TP53TG3 | 0.427 |
| ATP6AP1 | 0.426 |
| TP53TG3C | 0.426 |
| ANKLE2 | 0.425 |
| PAN2 | 0.425 |
| TRAPPC11 | 0.424 |
| SART1 | 0.423 |
| CNOT1 | 0.423 |
| PIGS | 0.423 |
| PSMD1 | 0.422 |
| PSMD2 | 0.422 |
| ATP6V1C1 | 0.422 |
| CCDC64B | 0.421 |
| VPS52 | 0.42 |
| AQR | 0.42 |
| GOLGA8O | 0.419 |
| AKAP1 | 0.418 |
| RPS19BP1 | 0.418 |
| PCF11 | 0.418 |
| NOP16 | 0.418 |
| COPA | 0.418 |
| HIST1H2BE | 0.416 |
| PSMA1 | 0.415 |
| EXOSC4 | 0.415 |
| UBAP1 | 0.414 |
| WDR87 | 0.414 |
| S1PR4 | 0.413 |
| GAR1 | 0.413 |
| POLR1A | 0.412 |
| TSPY8 | 0.412 |
| VASN | 0.412 |
| EXOSC5 | 0.412 |
| RANGAP1 | 0.412 |
| COPB2 | 0.411 |
| CTAGE9 | 0.411 |
| EXOSC9 | 0.411 |
| AHCTF1 | 0.41 |
| ZNF106 | 0.409 |
| RFFL | 0.409 |
| PDCD7 | 0.409 |
| RPS5 | 0.408 |
| TERF1 | 0.408 |
| SUPT5H | 0.408 |
| ATP6AP2 | 0.407 |
| TYMS | 0.406 |
| LOC643669 | 0.404 |
| TERF2 | 0.404 |
| GOSR2 | 0.404 |
| BYSL | 0.404 |
| C14orf93 | 0.404 |
| RPL6 | 0.404 |
| EXOSC3 | 0.404 |
| AATF | 0.404 |
| MYH7B | 0.403 |
| GID4 | 0.403 |
| COPB1 | 0.403 |
| NAPA | 0.402 |
| EBNA1BP2 | 0.401 |
| CCDC116 | 0.401 |
| TUBA8 | 0.401 |
| PSMB1 | 0.401 |
| RPS9 | 0.4 |
| GOLGA6A | 0.4 |
| RRP15 | 0.4 |
| SF3A3 | 0.4 |
Tissues where Essential in the Avana Dataset (DepMap 20Q1)
Global Fraction of Cell Lines Where Essential: 696/739
| Tissue | Fraction Of Cell Lines Where Essential |
|---|---|
| 1290807.0 | 1/1 |
| 909776.0 | 1/1 |
| bile duct | 24/28 |
| blood | 27/28 |
| bone | 25/26 |
| breast | 31/33 |
| central nervous system | 50/56 |
| cervix | 3/4 |
| colorectal | 16/17 |
| esophagus | 13/13 |
| fibroblast | 0/1 |
| gastric | 15/16 |
| kidney | 19/21 |
| liver | 18/20 |
| lung | 70/75 |
| lymphocyte | 16/16 |
| ovary | 26/26 |
| pancreas | 23/24 |
| peripheral nervous system | 16/16 |
| plasma cell | 15/15 |
| prostate | 1/1 |
| skin | 23/24 |
| soft tissue | 9/9 |
| thyroid | 2/2 |
| upper aerodigestive | 20/22 |
| urinary tract | 28/29 |
| uterus | 5/5 |
Essentiality in NALM6
- Essentiality Rank: 1401
- Expression level (log2 read counts): 4.53
Expression Distribution
ZNF830 Expression in NALM6 Cells: 4.53
